Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides

Infectious Disease Clinics of North America

Volumn 23, Issue 4, 2009, Pages 1053-1075

  Chen, Luke F ^a   Kaye, Donald ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

Aminoglycoside; Pharmacodynamics; Pharmacokinetics; Polymyxins; Rifampin; Rifaximin; Toxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CALCIUM; CEFTRIAXONE; CEPHALOSPORIN; COLISTIMETHATE; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; DOXYCYCLINE; GENTAMICIN; NETILMICIN; PENICILLIN G; POLYMYXIN B; POLYMYXIN DERIVATIVE; RIFAMYCIN DERIVATIVE; RIFAXIMIN; STREPTOMYCIN; TOBRAMYCIN; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; BARTONELLOSIS; BRONCHITIS; BRUCELLOSIS; CENTRAL NERVOUS SYSTEM INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DIAPHRAGM PARALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG USE; ENDOCARDITIS; EOSINOPHILIA; FEVER; FLU LIKE SYNDROME; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HAND PARESTHESIA; HEADACHE; HEARTBURN; HUMAN; INFLUENZA; INJECTION PAIN; INNER EAR DISEASE; LIVER FUNCTION TEST; LUNG INFECTION; MENINGOCOCCOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; NAUSEA; NEBULIZATION; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; NONHUMAN; OSTEOMYELITIS; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMOCOCCAL MENINGITIS; POSTANTIBIOTIC EFFECT; PROSTHETIC VALVE ENDOCARDITIS; Q FEVER; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOFT CONTACT LENS; STAPHYLOCOCCUS INFECTION; STEROID THERAPY; SWEAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; TRAVELLER DIARRHEA; TREATMENT INDICATION; URINE; VESTIBULAR DISORDER; VOMITING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; POLYMYXINS; RIFAMYCINS;

EID: 70449602617     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.06.004     Document Type: Review

References (144)

1. Hermsen E.D., Sullivan C.J., and Rotschafer J.C. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17 3 (2003) 545-562
2. Li J., Turnidge J., Milne R., et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45 3 (2001) 781-785
3. Kwa A., Kasiakou S.K., Tam V.H., et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 5 5 (2007) 811-821
4. Falagas M.E., and Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10 1 (2006) R27
5. Zavascki A.P., Goldani L.Z., Li J., et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60 6 (2007) 1206-1215
6. Falagas M.E., and Rafailidis P.I. Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives. Expert Opin Investig Drugs 17 7 (2008) 973-981
7. Reina R., Estenssoro E., Saenz G., et al. Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study. Intensive Care Med 31 8 (2005) 1058-1065
8. From A.H., Fong J.S., and Good R.A. Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun 23 3 (1979) 660-664
9. Gales A.C., Reis A.O., and Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39 1 (2001) 183-190
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (2008), Clinical and Laboratory Standards Institute (CLSI), Wayne (PA)
11. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 34 5 (2002) 634-640
12. Bengoechea J.A., and Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 37 1 (2000) 67-80
13. Evans M.E., Feola D.J., and Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33 9 (1999) 960-967
14. Zavascki A.P., Goldani L.Z., Cao G., et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47 10 (2008) 1298-1304
15. Nation R.L., and Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 28 6 (2007) 604-614
16. Reed M.D., Stern R.C., O'Riordan M.A., et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41 6 (2001) 645-654
17. Jimenez-Mejias M.E., Pichardo-Guerrero C., Marquez-Rivas F.J., et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 21 3 (2002) 212-214
18. Ratjen F., Rietschel E., Kasel D., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57 2 (2006) 306-311
19. Owen R.J., Li J., Nation R.L., et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59 3 (2007) 473-477
20. Bergen P.J., Li J., Nation R.L., et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61 3 (2008) 636-642
21. Gunderson B.W., Ibrahim K.H., Hovde L.B., et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47 3 (2003) 905-909
22. Giamarellos-Bourboulis E.J., Karnesis L., and Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44 3 (2002) 259-263
23. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 Suppl 2 (2006) S95-S99
24. Chitnis S., Chitnis V., and Chitnis D.S. In vitro synergistic activity of colistin with aminoglycosides, beta-lactams and rifampin against multidrug-resistant gram-negative bacteria. J Chemother 19 2 (2007) 226-229
25. Petrosillo N., Ioannidou E., and Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14 9 (2008) 816-827
26. Song J.Y., Lee J., Heo J.Y., et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 32 3 (2008) 281-284
27. Tascini C., Ferranti S., Messina F., et al. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 6 12 (2000) 690-691
28. Wallace S.J., Li J., Nation R.L., et al. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 52 3 (2008) 1159-1161
29. Bosso J.A., Liptak C.A., Seilheimer D.K., et al. Toxicity of colistin in cystic fibrosis patients. DICP 25 11 (1991) 1168-1170
30. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 9 (2003) 1111-1118
31. Rios F.G., Luna C.M., Maskin B., et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 30 2 (2007) 307-313
32. Falagas M.E., Bliziotis I.A., and Tam V.H. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 29 1 (2007) 9-25
33. FDA Alert [6/28/2007] Colistimethate (marketed as Coly-Mycin M and generic products) information. FDA. Available at:. http://www.fda.gov/DrugsSafety/PostmarketDrugSafetyInformationforPatient sandProviders/ucm118080.htm Accessed July 28, 2009
34. Segal-Maurer S., Mariano N., Qavi A., et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 28 5 (1999) 1134-1138
35. Gump W.C., and Walsh J.W. Intrathecal colistin for treatment of highly resistant pseudomonas ventriculitis. Case report and review of the literature. J Neurosurg 102 5 (2005) 915-917
36. Linden P.K., and Paterson D.L. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43 Suppl 2 (2006) S89-S94
37. Hartzell J.D., Kim A.S., Kortepeter M.G., et al. Acinetobacter pneumonia: a review. MedGenMed 9 3 (2007) 4
38. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 9 (2004) 1267-1284
39. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 7 6 (2001) 434-440
40. Maragakis L.L., and Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46 8 (2008) 1254-1263
41. Matthaiou D.K., Michalopoulos A., Rafailidis P.I., et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 36 3 (2008) 807-811
42. Huang D.B., and DuPont H.L. Rifaximin-a novel antimicrobial for enteric infections. J Infect 50 2 (2005) 97-106
43. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 3 (2007) CD004610
44. Paramasivan C.N., Sulochana S., Kubendiran G., et al. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 49 2 (2005) 627-631
45. Cappelletty D.M. Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy. Int J Antimicrob Agents 29 2 (2007) 212-216
46. Wehrli W., Knusel F., Schmid K., et al. Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci U S A 61 2 (1968) 667-673
47. Bundtzen R.W., Gerber A.U., Cohn D.L., et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis 3 1 (1981) 28-37
48. Thornsberry C., Hill B.C., Swenson J.M., et al. Rifampin: spectrum of antibacterial activity. Rev Infect Dis 5 Suppl 3 (1983) S412-S417
49. Pohlod D.J., Saravolatz L.D., and Somerville M.M. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin. J Antimicrob Chemother 20 2 (1987) 197-202
50. Klugman K.P., and Madhi S.A. Emergence of drug resistance. Impact on bacterial meningitis. Infect Dis Clin North Am 13 3 (1999) 637-646 vii
51. Watanakunakorn C., and Tisone J.C. Antagonism between nafcillin or oxacillin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 22 5 (1982) 920-922
52. Zak O., Scheld W.M., and Sande M.A. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis 5 Suppl 3 (1983) S481-S490
53. Kobasa W.D., Kaye K.L., Shapiro T., et al. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 5 Suppl 3 (1983) S533-S537
54. Karchmer A.W., Archer G.L., and Dismukes W.E. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 98 4 (1983) 447-455
55. Friedland I.R., Paris M., Ehrett S., et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 37 8 (1993) 1630-1636
56. Martinez-Lacasa J., Cabellos C., Martos A., et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 49 3 (2002) 507-513
57. Fitoussi F., Doit C., Geslin P., et al. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid. Antimicrob Agents Chemother 43 10 (1999) 2372-2375
58. Bassetti M., Repetto E., Righi E., et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61 2 (2008) 417-420
59. Baciewicz A.M., Chrisman C.R., Finch C.K., et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 335 2 (2008) 126-136
60. Mahatthanatrakul W., Nontaput T., Ridtitid W., et al. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 32 2 (2007) 161-167
61. Nijland H.M., L'Homme R.F., Rongen G.A., et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 22 8 (2008) 931-935
62. Fraser A., Gafter-Gvili A., Paul M., et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 4 (2006) CD004785
63. Fraser A., Gafter-Gvili A., Paul M., et al. Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials. Eur J Clin Microbiol Infect Dis 24 3 (2005) 172-181
64. Rainbow J., Cebelinski E., Bartkus J., et al. Rifampin-resistant meningococcal disease. Emerg Infect Dis 11 6 (2005) 977-979
65. Stefanelli P., Neri A., Carattoli A., et al. Detection of resistance to rifampicin and decreased susceptibility to penicillin in Neisseria meningitidis by real-time multiplex polymerase chain reaction assay. Diagn Microbiol Infect Dis 58 2 (2007) 241-244
66. Cuevas L.E., Kazembe P., Mughogho G.K., et al. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J Infect Dis 171 3 (1995) 728-731
67. Perlroth J., Kuo M., Tan J., et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 168 8 (2008) 805-819
68. Morris A.B., Brown R.B., and Sands M. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother 37 1 (1993) 1-7
69. Bayston R., Nuradeen B., Ashraf W., et al. Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection. J Antimicrob Chemother 60 6 (2007) 1298-1301
70. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111 23 (2005) e394-e434
71. Norden C.W. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis 5 Suppl 3 (1983) S491-S494
72. Bliziotis I.A., Ntziora F., Lawrence K.R., et al. Rifampin as adjuvant treatment of gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 26 12 (2007) 849-856
73. Falagas M.E., Bliziotis I.A., and Fragoulis K.N. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 35 2 (2007) 106-114
74. Simor A.E., Phillips E., McGeer A., et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 44 2 (2007) 178-185
75. Skalsky K., Yahav D., Bishara J., et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ 336 7646 (2008) 701-704
76. Ranjbar M., Keramat F., Mamani M., et al. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. Int J Infect Dis 11 2 (2007) 152-156
77. Pelosini I., and Scarpignato C. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. Chemotherapy 51 Suppl 1 (2005) 122-130
78. Ripa S., Mignini F., Prenna M., et al. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res 13 8 (1987) 483-488
79. DuPont H.L., and Jiang Z.D. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 10 11 (2004) 1009-1011
80. Brigidi P., Swennen E., Rizzello F., et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 14 3 (2002) 290-295
81. Adachi J.A., and DuPont H.L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 42 4 (2006) 541-547
82. DuPont H.L., Jiang Z.D., Ericsson C.D., et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 33 11 (2001) 1807-1815
83. DuPont H.L., Ericsson C.D., Mathewson J.J., et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 59 6 (1998) 708-714
84. Steffen R., Sack D.A., Riopel L., et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 98 5 (2003) 1073-1078
85. Trapnell C.B., Connolly M., Pentikis H., et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 41 2 (2007) 222-228
86. Garey K.W., Salazar M., Shah D., et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 42 6 (2008) 827-835
87. Halsey J. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65 8 (2008) 705-715
88. Kokkotou E., Moss A.C., Michos A., et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother 52 3 (2008) 1121-1126
89. Berman A.L. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 41 10 (2007) 932-933
90. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44 6 (2007) 846-848
91. Drusano G.L., Ambrose P.G., Bhavnani S.M., et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45 6 (2007) 753-760
92. Falagas M.E., Matthaiou D.K., and Bliziotis I.A. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57 4 (2006) 639-647
93. Lentino J.R., Narita M., and Yu V.L. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 27 1 (2008) 3-15
94. Rea R.S., and Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 28 6 (2007) 596-603
95. Cunha B.A. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am 90 6 (2006) 1089-1107
96. Friedland I., Gallagher G., King T., et al. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. J Chemother 16 5 (2004) 437-441
97. Buijk S.E., Mouton J.W., Gyssens I.C., et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28 7 (2002) 936-942
98. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 17 3 (2003) 503-528 v
99. Isaksson B., Maller R., Nilsson L.E., et al. Postantibiotic effect of aminoglycosides on staphylococci. J Antimicrob Chemother 32 2 (1993) 215-222
100. Isaksson B., Nilsson L., Maller R., et al. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 22 1 (1988) 23-33
101. McDonald P.J., Wetherall B.L., and Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 3 1 (1981) 38-44
102. Kapusnik J.E., Hackbarth C.J., Chambers H.F., et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 158 1 (1988) 7-12
103. Baudoux P., Bles N., Lemaire S., et al. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 59 2 (2007) 246-253
104. Simmen H.P., Battaglia H., Kossmann T., et al. Effect of peritoneal fluid pH on outcome of aminoglycoside treatment of intraabdominal infections. World J Surg 17 3 (1993) 393-397
105. Harrell L.J., and Evans J.B. Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides. Antimicrob Agents Chemother 14 6 (1978) 927-929
106. Barclay M.L., and Begg E.J. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 61 6 (2001) 713-721
107. Daikos G.L., Lolans V.T., and Jackson G.G. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 35 1 (1991) 117-123
108. Chandrakanth R.K., Raju S., and Patil S.A. Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates. Curr Microbiol 56 6 (2008) 558-562
109. Verpooten G.A., Giuliano R.A., Verbist L., et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 45 1 (1989) 22-27
110. Bennett W.M., Plamp C.E., Gilbert D.N., et al. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 140 4 (1979) 576-580
111. Rybak M.J., Abate B.J., Kang S.L., et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43 7 (1999) 1549-1555
112. Beauchamp D., and Labrecque G. Chronobiology and chronotoxicology of antibiotics and aminoglycosides. Adv Drug Deliv Rev 59 9-10 (2007) 896-903
113. Baciewicz A.M., Sokos D.R., and Cowan R.I. Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother 37 2 (2003) 182-186
114. Rougier F., Claude D., Maurin M., et al. Aminoglycoside nephrotoxicity. Curr Drug Targets Infect Disord 4 2 (2004) 153-162
115. Rybak L.P., and Ramkumar V. Ototoxicity. Kidney Int 72 8 (2007) 931-935
116. Tran Ba Huy P., Bernard P., and Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 77 5 (1986) 1492-1500
117. Gatell J.M., Ferran F., Araujo V., et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 31 9 (1987) 1383-1387
118. Ariano R.E., Zelenitsky S.A., and Kassum D.A. Aminoglycoside-induced vestibular injury: maintaining a sense of balance. Ann Pharmacother 42 9 (2008) 1282-1289
119. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39 3 (1995) 650-655
120. Prins J.M., Weverling G.J., de Blok K., et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40 11 (1996) 2494-2499
121. Graham J.C., and Gould F.K. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 49 3 (2002) 437-444
122. Smyth A.R., and Tan K.H. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 3 (2006) CD002009
123. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 12 6 (2006) 428-432
124. Wood D.M., and Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 1 (2006) CD004197
125. Smyth A., Tan K.H., Hyman-Taylor P., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 365 9459 (2005) 573-578
126. Weiner J.R., Toy E.L., Sacco P., et al. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother 9 5 (2008) 751-766
127. Dopfer R., Brand P., Mullinger B., et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J Physiol Pharmacol 58 Suppl 5 Pt 1 (2007) 141-154
128. Lenoir G., Antypkin Y.G., Miano A., et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 9 Suppl 1 (2007) 11-20
129. Goss C.H. Should we stop using intravenous gentamicin in patients with cystic fibrosis?. Thorax 63 6 (2008) 479-480
130. de Groot R., and Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 13 4 (1987) 228-253
131. Vic P., Ategbo S., Turck D., et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 78 6 (1998) 536-539
132. Bragonier R., and Brown N.M. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 42 1 (1998) 103-106
133. Banerjee D., and Stableforth D. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?. Drugs 60 5 (2000) 1053-1064
134. Beringer P.M., Vinks A.A., Jelliffe R.W., et al. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 44 4 (2000) 809-813
135. Byl B., Baran D., Jacobs F., et al. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 48 2 (2001) 325-327
136. Touw D.J., Knox A.J., and Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 6 5 (2007) 327-333
137. Al-Lanqawi Y., Capps P., Abdel-hamid M., et al. Therapeutic drug monitoring of gentamicin: evaluation of five nomograms for initial dosing at Al-Amiri hospital in Kuwait. Med Princ Pract 16 5 (2007) 348-354
138. Barclay M.L., Kirkpatrick C.M., and Begg E.J. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?. Clin Pharmacokinet 36 2 (1999) 89-98
139. Bailey T.C., Little J.R., Littenberg B., et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24 5 (1997) 786-795
140. Tod M.M., Padoin C., and Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?. Clin Pharmacokinet 40 11 (2001) 803-814
141. Barclay M.L., Duffull S.B., Begg E.J., et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med 25 3 (1995) 230-235
142. Paterson D.L., Robson J.M., Wagener M.M., et al. Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology 30 3 (1998) 289-294
143. Bartal C., Danon A., Schlaeffer F., et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 114 3 (2003) 194-198
144. Urban A.W., and Craig W.A. Daily dosage of aminoglycosides. Curr Clin Top Infect Dis 17 (1997) 236-255